DBR1 analysis is crucial for developing novel antiviral strategies, particularly against retroviruses like HIV-1. By studying DBR1's role in viral replication cycles and its impact on the stability of viral RNA lariats, researchers can identify specific vulnerabilities and design targeted inhibitors, thereby preventing viral propagation.
Creative Biolabs stands as a leader in CRO services, backed by decades of experience and a highly skilled team of scientists dedicated to biomarker research. Our premier biomarker analysis services, enhanced by a cutting-edge technology platform and extensive expertise in in vitro diagnostics (IVD), are available at competitive pricing. We now provide custom human debranching RNA Lariats 1 (DBR1) analysis services for global clients.
Introduction of DBR1
Human DBR1 protein comprises 544 amino acids, featuring a highly conserved catalytic GNHE motif crucial for its enzymatic function and a bipartite nuclear localization signal (NLS) dictating its cellular location. DBR1 plays an indispensable regulatory role in pre-mRNA processing events, including the critical steps of pre-mRNA splicing and subsequent intron turnover. Moreover, the essential biogenesis of diverse non-coding RNAs, particularly those derived from intronic regions, is profoundly dependent on DBR1 activity. Consequently, any inhibition or dysregulation of DBR1 can disrupt cellular homeostasis and impair the fundamental functions of these vital non-coding RNAs. Diseases strongly associated with DBR1 dysfunction primarily include aggressive conditions such as esophageal squamous cell carcinoma (ESCC), colorectal cancer, and severe forms of viral encephalitis.
Fig.1 Structure of human DBR1.1
DBR1 Analysis Services at Creative Biolabs
Creative Biolabs provides a comprehensive suite of DBR1 analysis services, meticulously designed to support your research and development needs. These services encompass a wide range of analytical approaches, including functional assays, advanced molecular analysis, and the development of robust cellular and disease models, all tailored to accelerate your understanding of DBR1's biological roles and its therapeutic potential.
- DBR1 siRNA Design
- Protein Detection
- Creation of DBR1 Point Mutant Strains
- DBR1 Single Gene Test
siRNA-mediated inhibition of expression of the human DBR1 would specifically inhibit HIV-1 replication during reverse transcription. To support the role study of DBR1 in HIV reverse transcription, Creative Biolabs provides DBR1 shRNA knockdown construct generation services for global clients. DBR1 mRNA levels will be analyzed by quantitative reverse transcription-PCR.
The detection of DBR1 protein expression in tissue chips could be performed by IHC staining. A commercial human DBR1 ELISA Kit could also be used for the in vitro quantitative measurement of human DBR1 concentrations in tissue homogenates, cell lysates, and other biological fluids.
Mutants could be created using modifications of the delitto perfetto method and the site-specific genomic (SSG) method. Analyzing mutant variants of DBR1 will be achieved by qRT-PCR.
Our single gene tests are sectioned from our high-quality NGS assay. Assays have been validated for various sample types including EDTA-blood and isolated DNA. These sample types were selected to maximize the likelihood of high-quality DNA yield.
Fig.2 The analysis approaches of DBR1.
Creative Biolabs assists you with further DBR1 analysis including but not limited to the following:
- Functional analysis of recombinant human DBR1
- Binding site characterization via ELISA
- Protein genetic engineering
- Protein expression
- Assay development
Service Workflow
01Initial Consultation & Project Scope
Our expert scientists will first conduct a thorough consultation with you to understand your specific research objectives, experimental needs, and desired outcomes for the DBR1 analysis. This ensures that the project is precisely aligned with your goals.
02Client Material Submission
Following the consultation, you will provide the necessary starting materials. These can include purified DBR1 protein, various cell lines (such as HEK293T, iPSC-derived neurons), fresh or frozen tissue biopsies, or isolated RNA/DNA preparations, depending on the agreed-upon analysis.
03Experimental Design & Protocol Implementation
Our team will then develop a customized experimental design based on your project scope. We will implement validated protocols utilizing our state-of-the-art technology platform for precise measurements of enzymatic activity, detailed characterization of protein interactions, or comprehensive quantification of lariat RNA accumulation.
04Data Acquisition & Analysis
Experiments are meticulously performed, and data is rigorously collected. Our experienced bioinformatics and data analysis teams process this information, ensuring accuracy and preparing it for insightful interpretation.
05Quality Control & Verification
Throughout the process, stringent quality control measures are applied at every stage, from sample handling to data processing. This includes internal checks and validations to guarantee the reliability and reproducibility of all results.
06Comprehensive Report & Data Delivery
Finally, we deliver a comprehensive report detailing all experimental procedures, raw data files, and expert interpretations of the findings. This ensures you receive actionable insights that directly address your initial research questions.
Applications
Advancing Antiviral Therapeutics
Neurological Disease Research
Investigating DBR1 function is pivotal in understanding and treating neurological disorders such as viral encephalitis, ALS, and FTLD. Analyzing DBR1 activity and lariat RNA accumulation in patient-derived models allows for the identification of disease biomarkers and the development of therapeutic compounds aimed at restoring RNA homeostasis or sequestering toxic protein aggregates.
Cancer Biology and Diagnostics
DBR1 expression and activity are implicated in various cancers, including esophageal squamous cell carcinoma and colorectal cancer. Comprehensive DBR1 analysis aids in identifying its precise role in oncogenesis, enabling the discovery of novel diagnostic markers for early detection and the development of targeted therapies that exploit DBR1-related pathways.
Non-Coding RNA Biogenesis Studies
Understanding DBR1's role in the maturation of essential non-coding RNAs like snoRNAs and microRNAs is critical for unraveling complex gene regulatory networks. DBR1 analysis facilitates detailed studies into the biogenesis pathways of these RNAs, revealing how their dysregulation contributes to disease pathology and opening avenues for RNA-based therapies.
Service Highlights
- Expert-Led Consultation: Our service begins with expert-led consultations, leveraging our scientists' decades of specialized RNA biology and biomarker research experience to precisely align with your project goals.
- Advanced Analytical Platform: We utilize a state-of-the-art technology platform, incorporating cutting-edge techniques like quantitative RT-PCR, lariat-seq, and smFISH, ensuring high-resolution data and comprehensive insights into DBR1 activity.
- Customized Experimental Design: Every DBR1 analysis project is uniquely tailored to your specific needs, enabling the development and characterization of custom DBR1 knockout/knockdown cell lines and bespoke assays for precise research objectives.
- Rapid Turnaround and Comprehensive Reporting: Creative Biolabs delivers prompt, reliable results through detailed reports and raw data, expediting your research timelines and facilitating quicker decision-making in drug discovery efforts.
FAQs
-
Can you develop custom DBR1 assays tailored to specific research questions?
Creative Biolabs absolutely specializes in developing custom DBR1 assays, and our expert team will collaborate closely with you to design and validate bespoke functional, molecular, or cellular assays that precisely address your unique research objectives, ensuring highly relevant and specific data.
-
What quality control measures are in place to ensure the accuracy of DBR1 analysis results?
Creative Biolabs implements rigorous quality control measures at every stage of DBR1 analysis, encompassing meticulous sample handling, stringent reagent validation, standardized assay protocols, and multi-layered data verification by experienced scientists, thereby guaranteeing the utmost accuracy and reliability of all reported results.
-
Can DBR1 analysis identify specific mutations or variants associated with disease?
DBR1 analysis can certainly identify specific mutations or genetic variants associated with disease, particularly through advanced molecular techniques like next-generation sequencing in cellular models, providing crucial insights into the genetic basis of DBR1-related pathologies.
-
Do you offer follow-up consultation after the project is completed?
We are committed to fostering long-term partnerships and offering dedicated follow-up consultations after project completion, ensuring you have ample opportunity to discuss the results, plan next steps, and explore potential avenues for further collaboration with our scientific team.
-
How can DBR1 analysis contribute to preclinical drug development for neurological diseases?
DBR1 analysis significantly contributes to preclinical drug development for neurological diseases by enabling the identification of therapeutic targets, facilitating the screening and optimization of drug candidates, and providing mechanistic insights into how compounds mitigate disease progression by modulating DBR1 activity or its downstream effects on RNA metabolism.
Our biomarker analysis service is furnished for academic research only. Not for use in diagnostic procedures. If you want to order this test, please feel free to contact us for more information.
Reference
- Clark, Nathaniel E., et al. "Activation of human RNA lariat debranching enzyme Dbr1 by binding protein TTDN1 occurs though an intrinsically disordered C-terminal domain." Journal of Biological Chemistry 299.9 (2023). Distributed under Open Access license CC BY 4.0, without modification.
For Research Use Only.
